Apollomics (APLMW) Stock Price, News & Analysis

Company Overview

Apollomics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies in the field of immuno-oncology. The company’s research focuses on novel small molecules designed to modulate key pathways involved in tumor growth and immune evasion. Apollomics leverages a combination of proprietary chemistry and translational biology to advance its pipeline candidates from preclinical studies into human trials.

The company’s lead programs include APG-115, an MDM2 inhibitor aimed at restoring p53 tumor suppressor activity, and APG-1252, a BCL-2/BCL-XL inhibitor prodrug engineered to induce apoptosis in cancer cells resistant to conventional therapies. Additional assets, such as APG-2449 (a multi-kinase inhibitor targeting FGFR and MET), further reflect Apollomics’ strategy of addressing multiple tumor types through targeted mechanisms. These candidates are being evaluated in Phase 1/2 trials across the United States and China, with several combination studies planned to explore synergistic approaches with established immunotherapies.

Apollomics operates from its corporate headquarters in Fremont, California, with research and development facilities in Shanghai. The company’s leadership team combines drug development expertise from both U.S. and Chinese oncology markets, supporting a global footprint in clinical operations and regulatory interactions. Through strategic collaborations and a cross-border infrastructure, Apollomics aims to accelerate the availability of its therapies to patients worldwide.

Key Stats

• Today's Range: $0.02 to $0.03
• 50-Day Range: $0.01 to $0.04
• 52-Week Range: $0.01 to $0.05
• Volume: 57,400 shs
• Average Volume: 86,282 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

APLMW Stock Analysis - Frequently Asked Questions

How have APLMW shares performed this year?

Apollomics' stock was trading at $0.0092 at the start of the year. Since then, APLMW stock has increased by 256.5% and is now trading at $0.0328.

How do I buy shares of Apollomics?

Shares of APLMW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NASDAQ:APLMW
• CIK: 1944885
• Web: www.apollomicsinc.com
• Phone: 650-209-4055
• Fax: N/A
• Employees: 59
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A